[Beta-adrenergic inhibitors and portal hypertension]

Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis.

Alimentary pharmacology & therapeutics·2018

Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis.

Alimentary pharmacology & therapeutics·2016

Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population.

Journal of hepatology·2010

[Progress in portal hypertension].

Gastroenterologie clinique et biologique·2009

Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats.

The European respiratory journal·2009

Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites.

Acta gastro-enterologica Belgica·2008

Characteristics of patients with opioid/benzodiazepine use disorder in a specialized consultation unit for prescription drug addiction: A cross-sectional study.

Therapie·2026

Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.

Therapie·2026

[Biological pharmacology: A white paper].

Therapie·2026

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026

[Pharmacologic treatment of dystonia].

Medicina·2026

From bench to bedside: experimental pharmacology approaches to overcome bioavailability, stability, and translational barriers of bioactive peptides from natural sources.

Frontiers in pharmacology·2026

Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.

Pharmaceuticals (Basel, Switzerland)·2026

Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors.

Pharmaceuticals (Basel, Switzerland)·2026

Novel Roles of Urokinase- and Tissue-Type Plasminogen Activators in Substance Use Disorders: A Narrative Review of Molecular Mechanisms and Translational Perspectives.

International journal of molecular sciences·2026

Unraveling Effects and Pharmacological Mechanisms of Phellodendrine on Inflammatory Bowel Disease.

Biomolecules·2026

Related Experiment Videos

[Beta-adrenergic inhibitors and portal hypertension]

Related Concept Videos

Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis.

Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis.

Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population.

[Progress in portal hypertension].

Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats.

Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites.

Characteristics of patients with opioid/benzodiazepine use disorder in a specialized consultation unit for prescription drug addiction: A cross-sectional study.

Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.

[Biological pharmacology: A white paper].

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

[Pharmacologic treatment of dystonia].

From bench to bedside: experimental pharmacology approaches to overcome bioavailability, stability, and translational barriers of bioactive peptides from natural sources.

Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.

Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors.

Novel Roles of Urokinase- and Tissue-Type Plasminogen Activators in Substance Use Disorders: A Narrative Review of Molecular Mechanisms and Translational Perspectives.

Unraveling Effects and Pharmacological Mechanisms of Phellodendrine on Inflammatory Bowel Disease.

Related Experiment Videos

[Beta-adrenergic inhibitors and portal hypertension]

Related Concept Videos

Related Articles